ArticleThe Kaohsiung journal of medical sciences2025
Hepatitis C virus-free endoscope procedures project: An in-hospital elimination approach.
Article in The Kaohsiung journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Real-World Impact of a Simplified 'Test and Treat' Strategy for In-Hospital HCV Micro-Elimination.Journal of viral hepatitis · 2026Article
- Hepatitis C virus-free endoscope procedures project: An in-hospital elimination approach.The Kaohsiung journal of medical sciences · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus (HCV) elimination in the care cascades for patients receiving invasive procedures remains elusive. This study aimed to evaluate the efficacy of HCV-free Endoscope Procedures Project (CEPP) in the effort toward hospital HCV micro-elimination in Taiwan. An electronic medical record (EMR)-based remind system was introduced into gastrointestinal, surgical, urological, and gynecological departments prior to the endoscopy procedures. Anti-HCV tests were actively ordered on their EMR among those patients who have not been tested in the past 5 years. Those patients with anti-HCV+ were recruited into the care cascade for HCV treatment, including HCVRNA testing, direct antivirals (DAAs) delivery, and treatment response assessment. We divided the elimination project into two phases: before (2020 Jan to 2020 Dec, phase A) and during (2021 Jan to 2022 Sep, phase B) the remind system. The screening rate of phase B was 64.2% (1857/2893), which was significantly higher than phase A (18.7%, 899/4812) (p < 0.001). The screening rate of Department of Medicine (DOM) significantly increased from 21.1% of phase A to 89.3% of Phase B (p < 0.001). During phase B, the screening rate of non-DOM was 48.2%, which was significantly higher than 11.8% of Phase A (p < 0.001). During Phase B, 15 (0.8%) out of 1857 screened patients were HCVRNA+. Six HCVRNA+ patients received DAAs treatment, and all achieved viral eradication. The CEPP significantly increased the anti-HCV screening rate for subsequent care cascades, particularly in patients of DOM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.